Login to Your Account



AVI BioPharma Stock Soars On Preclinical Flu Outcomes

By Randall Osborne


Monday, January 23, 2006
Almost exactly one year to the day after antisense firm AVI BioPharma Inc.'s stock shot up on news about its stem cell patents, positive preclinical findings against avian H5N1 influenza and human strains sent the company's shares on another skyward ride. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription